Concepedia

Author

Leopoldo Martín Baiza-Durán

Laboratorios Sophia (Mexico)

Also Known As

Baiza-Duran L, Baiza-Duran,Leopoldo, Baiza-Durán,Leopoldo Martín, L M Baiza-Duran, L. Baiza-Duran, L. Baiza-Durán, L.M. Baiza-Duran, Leopoldo Baiza-Duran, Leopoldo Baiza-Durán, Leopoldo Baiza‐Duran

68

Publications

362

Citations

12

H-Index

0

Concepts

All Affiliations

Laboratorios Sophia (Mexico)Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez BulnesHospital Civil de GuadalajaraInstituto Politécnico NacionalCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional
LM

About

Leopoldo Martín Baiza-Durán is an author at Laboratorios Sophia (Mexico).

Leopoldo Martín Baiza-Durán

×

11

Publications

245

Citations

11

H-Index

YearCitations

A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome

Leopoldo Martín Baiza-Durán, Javier Medrano-Palafox, Everardo Hernández-Quíntela,

British Journal of Ophthalmology

2010

57

Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial

Sandra Belalcázar-Rey, Valeria Sánchez-Huerta, Juan Carlos Ochoa-Tabares,

Current Eye Research

2020

30

Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye

Leopoldo Martín Baiza-Durán, Saucedo-Rodríguez, Alaníz-De la O,

Clinical ophthalmology

2013

22

Comparison of the Stability, Efficacy, and Adverse Effect Profile of the Innovator 0.005% Latanoprost Ophthalmic Solution and a Novel Cyclodextrin‐containing Formulation

Jaime R González, Leopoldo Martín Baiza-Durán, Juan D Quintana-Hau,

The Journal of Clinical Pharmacology

2006

22

Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation

Raymundo Cruz, Juan D Quintana-Hau, J R Gonzalez,

British Journal of Ophthalmology

2007

22

<p>Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model</p>

Oscar Olvera‐Montaño, Leopoldo Martín Baiza-Durán, Juan D Quintana-Hau,

Drug Design Development and Therapy

2019

19

The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.

Leopoldo Martín Baiza-Durán, Jaime Álvarez-Delgado, Angélica Yussett Contreras-Rubio,

PubMed

2010

16

Characterization of the Novel Ophthalmic Drug Carrier Sophisen in Two of Its Derivatives: 3A Ofteno™ and Modusik-A Ofteno™

Juan D Quintana-Hau, E. Cruz–Olmos, Miriam Lopez-Sanchez,

Drug Development and Industrial Pharmacy

2005

16

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension

Leopoldo Martín Baiza-Durán, Juan Francisco Llamas-Moreno, Clotilde Ayala-Barajas,

Clinical ophthalmology

2012

15

Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate

Alejandra Sánchez‐Ríos, Elba Yadira Correa‐Gallegos, José Manuel Medina‐Espinoza,

Animal Models and Experimental Medicine

2022

14

Page 1